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Abstract
Background: T cells are closely linked to the clinical manifestations of subjects with Mycobacterium tuberculosis
(MTB) infection. T cell receptor beta variable (TCRBV) is a signal and indicative molecule on the membrane of
T lymphocytes, reflecting the composition and specificity of T cells. The molecular profiles of TCRBV in peripheral
blood mononuclear cells (PBMCs) and their subpopulations (CD4+ and CD8+ T cells) from subjects with active
tuberculosis (TB) or latent TB infection (LTBI) have not been well described.
Methods: In 42 subjects with active TB or LTBI, PMBCs and their subsets were separated and sorted. The molecular
profiles of the TCRBV complementarity determining region 3 (CDR3) in the three cell populations were investigated
using our recently developed gene melting spectral pattern (GMSP) assay. The TCRBV members were then cloned
and sequenced when their GMSP image profiles showed a single-peak.
Results: The average number of skewed TCRBV molecules in the CD4+ cell subset was significantly higher than that
in PBMCs and CD8+ T cells. TCRBV12, BV13.1, BV13.2, and BV24 were expressed more prevalently than other TCRBV
gene families in the three cell populations. In addition, relatively conserved amino acid motifs were identified in
TCRBV5.1 and BV20 CDR3 in PBMCs and its subsets. The monoclonal TCRBV14 and BV23 expressed were different
between active TB and LTBI subjects.
Conclusions: These results indicate that the T cell immune response is complex and multi-specific in active TB and
LTBI subjects. Analysis of TCRBV expression in CD4+ T cells suggest that it could be useful in assessing the
composition and status of circulating T cells. Furthermore, the expression of TCRBV14, BV23 and the sequencing of
CDR3 amino acid motifs of TCRBV5.1, BV20 could be used in the differential diagnosis and treatment of subjects
with active TB or LTBI.
Background
Tuberculosis (TB) is the most common opportunistic in-
fection caused by Mycobacterium tuberculosis (MTB), and
is a serious global public health problem. According to the
2012 World Health Organization (WHO) report, about 1.4
million people, of which 500,000 were female, died from
MTB infection. About 8.7 million subjects were newly
infected with TB in 2011, including 500,000 children [1].
Clinical experience suggests that early diagnosis and
treatment are key to improving the prognosis of TB pa-
tients, and are important factors in controlling the spread
of TB [2], significantly reducing fatality. The commercial
enzyme-linked immunospot assay (T-SPOT.TB) based
on the interferon (IFN)-gamma release assay (IGRA) is
useful in diagnosing subjects infected with MTB, with
high sensitivity and specificity [3,4]. The T-SPOT.TB
assay can help to distinguish subjects with latent TB
infection (LTBI) from those vaccinated with Bacillus
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Calmette-Guerin (BCG) [5,6], but cannot directly distin-
guish between subjects with active TB and LTBI [7,8].
T cells play a key role in the control of MTB infection in
vivo, especially the CD4+ T cell population [9-11]. The
T cell receptor (TCR) repertoire can reflect the specificity,
status, and composition of T cell populations. However,
the molecular characterization of TCRBV in the peripheral
blood of subjects with MTB infection is not well described
[12]. Characterization of the TCR repertoire of T cells and
its subsets (CD4+ and CD8+ T cells) in MTB subjects may
help clarify the role of T cells in TB pathogenesis. Further-
more, understanding the difference in TCR expression
between active TB and LTBI, may aid diagnosis and the
development of personalized treatment in subjects with
MTB, especially in active TB patients. In this study, CD4+
and CD8+ T cell subsets were obtained using a magnetic
bead separation technique, and characterization of the
TCRBV CDR3 in these cell populations as well as in per-
ipheral blood mononuclear cells (PBMCs) from subjects
with active TB or LTBI was investigated using gene melt-
ing spectral pattern (GMSP) assay.
Methods
Subjects
All participants were recruited in the First Affiliated
Hospital, College of Medicine, Zhejiang University over
a 6-month period from November 2011 through April
2012. A heparinized blood sample was drawn following
informed consent. The study was conducted according
to the guidelines of the Declaration of Helsinki. The
medical ethics committee of the First Affiliated Hospital,
Zhejiang University approved all procedures involving
human subjects.
Forty-two subjects with a positive T-SPOT.TB assay
were recruited. Of these, active TB was diagnosed in 22
cases including 15 with pulmonary tuberculosis, 4 with
pulmonary tuberculosis with pleurisy, 2 with pulmonary
tuberculosis and intestinal tuberculosis, and 1 case with
tuberculous pleurisy. These 22 cases had positive spu-
tum/bronchial alveolar lavage (BAL) acid fast bacilli
(AFB) stains and/or culture for MTB. Sputum and BAL
were cultured according to National Center for Clinical
Laboratory Standards for 6 weeks in a liquid (BACTEC
MGIT 960, BD Biosciences) and using a solid medium
(BD Biosciences). The remaining 20 cases had no history
of active tuberculosis, and the clinical diagnosis of latent
tuberculosis infection (LTBI) was based on nucleic acid
specimens tested positive by PCR for MTB and typical
imaging information. This pattern with LTBI was more
described in previously report [13]. Of these subjects, 1
also had irritable bowel syndrome (IBS), 3 had a small
ulcer, 2 had pericardial effusion and 1 had pleurisy, and
the remaining patients with latent pulmonary TB.
Subjects were excluded if they were co-infected with
other infectious diseases, such as human immunodefi-
ciency virus (HIV), or overt cytomegalovirus (CMV) infec-
tion. Subjects with severe liver disease and kidney failure
were also excluded. None of the enrolled patients used im-
munosuppressive agents or enhancers. Additional infor-
mation on the enrolled subjects is shown in Table 1.
Isolation of PBMCs, CD4+ and CD8+ T cell sorted
Peripheral blood mononuclear cells (PBMCs) from 42
subjects with active TB or LTBI were obtained from fresh
heparinized blood by density gradient centrifugation on
Ficoll-Paque (CEDARLANE, Netherlands). CD4+ and
CD8+ T cells were positively selected from PBMCs using
anti-CD4/anti-CD8 monoclonal antibodies coupled to
antibody-coated magnetic beads (Miltenyi Biotec,
Bergisch Gladbach, Germany), according to the manu-
facturer’s instructions. Purity of the separated CD4+ and
CD8+ T cell populations were tested by Flow Cytometry
(FCM) analysis using FITC-labeled anti-CD4 and PE-
labeled anti-CD8 monoclonal antibodies, respectively. The
T cell subpopulations were found to be more than 95%
purity (data not shown).
RNA extraction and cDNA synthesis
Total RNA was extracted from PBMCs (CD4+ and CD8+
T cell subpopulations) using a SV Total RNA Isolation
System (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. RNA was quantified using a
NanoDropW ND-2000 spectrophotometer (Thermo Fisher
Scientific, Wilmington, Delaware, USA), and its integrity
was confirmed electrophoretically (including 28S and
18S band on 2% agarose gel electrophoresis). Total
RNA was immediately reverse transcribed to cDNA
using the RevertAid First Strand cDNA Synthesis Kit
Table 1 Demographic and clinical characteristics of the
subjects enrolled in the studya
Total number Active TB LTBI
(n = 42) (n = 22) (n = 20)
Age 47.0 ± 14.1 46.2 ± 15.4 48.6 ± 13.1
Male 26 15 11
BCG
Vaccinated 25 13 12
Unvaccinated 14 8 6
NA 3 1 2
T-SPOT. TB
Positive 42 22 20
Negative - - -
aAll enrolled subjects are Chinese Han population.
LTBI latent TB infection, TB tuberculosis, BCG Bacillus Calmette - Guerin,
T-SPOT. TB the commercial enzyme-linked immunospot assay,
NA not available.
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(MBI, Fermentas, EU) according to the manufacturer’s
instructions. Briefly, 1–5 μg total RNA was reverse tran-
scribed with OligodT18 as primer in a 20 μL reaction
volume and stored at −25°C.
GMSP assay of TCRBV in PBMCs, CD4+ and CD8+ T cells
The GoTaq® qPCR Master Mix (with Rox™ dye)
(Promega, Madison, WI, USA) was used as the real-time
PCR kit. A Mastermix of 25 μl for each of the 28 reac-
tions containing 0.4 μM reverse primer TCRBC, and
50 ~ 150 ng template cDNA was prepared. For TCRBV
gene families specific amplification, the corresponding
forward primer (TCRBV1 ~ 24) was added to a final con-
centration of 0.4 μM. The real-time PCR reaction pa-
rameters were as follows: 2 min at 95°C to activate the
GoTaq enzyme, followed by 45 cycles at 95°C for 15 s,
56.0°C for 25 s, and 72°C for 35 s with a final extension
at 72°C for 8 min, following the PCR products melting
curve analysis. The peak shape pattern of the melting
curve for 24 TCRBV gene families was determined by
plotting the first negative derivative of the decrease in
fluorescence signal versus temperature (−dF/dT) versus
temperature (Tm), generating gene melting spectral pat-
terns (GMSPs) as previously reported [14,15]. The sim-
ultaneous amplification of TCR beta chain constant 1
(TCRBC1) and glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) gene segments were used as positive
(monoclonal) controls.
Relative frequency of TCRBV families
The expressing frequency of each TCRBV family in T-
cell populations was calculated based on signal strength
of the real-time PCR reactions, and expressed as the ra-
tio of the copy number between TCRBV and GAPDH
(RBVx = 2^
Ct (GAPDH)-Ct (BVx)), where Ct refers to thresh-
old cycle. The relative TCRBVx gene frequency (%) was
calculated according to the following formula [16,17].
TCRBVx %ð Þ ¼ RBVx 100=
X24
¼1RBVx
Identification of skewed TCRBV families
A skewed TCRB gene family was defined using the pro-
file of each GMSP image displayed by the software
(Opticon Monitor 3.0) attached to the MJ Opticon 2
DNA engine (Bio-Rad, USA), and included two categor-
ies: 1) “Oligoclonal expansion”, appearing as a main peak
associated with other small peaks on the GMSP, and the
small peak with a height less than half the height of the
main peak; and 2) the “Monoclonal” category, with only
one main peak, and a very short small peak or no add-
itional peak. Further details are described in our previ-
ously published report [15].
Cloning and sequencing
If a TCRBV gene family showed a monoclonal GMSP pro-
file (single peak shape), the sample was selected for
cloning and sequencing to determine the degree of homo-
geneity within the CDR3 region. Briefly, the PCR products
were re-amplified using GoTaq DNA polymerase
(Promega, Madison, WI, USA) by touchdown PCR. The
parameters were as follows: pre-incubation at 95°C for
2 min, 95°C for 30 s, 60°C for 40 s, and 72°C for 45 s, for
8 cycles with annealing temperature decreasing 0.5°C per
cycle, and 95°C for 45 s, 56°C for 45 s, and 72°C for 50 s,
for 27 cycles. The cycling was followed by a terminal elong-
ation step at 72°C for 8 min. The nest-PCR products were
separated using 2% (0.5% Tris-buffered EDTA) agarose gels
(FMV BioProducts, Rockland, ME, USA), excised, and puri-
fied using a QIAEX gel extraction kit (Qiagen, Germany).
Purified PCR products were ligated into pGEMT-T using
the pGEM-3Z Cloning Kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Cloning de-
tails have been described previously [18]. The plasmid
DNA was sequenced using an ABI3730 DNA Sequencer
(Applied Biosystems, Foster City, CA, USA).
The resulting sequences (nucleotide) were compared
against sequences in the IMGT-LIGM database (http://
www.imgt.org), and translated into their correspon-
ding amino acids using Chromas software version
2.22 (Technelysium Ltd., South Brisbane, Queensland,
Australia). BLAST (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) was used to define CDR3 and BJ segments in the
TCRBV gene families [17,19].
Statistical analysis
All data were analysed using SPSS software version 16.0
(SPSS Inc., Chicago, IL, USA). The differences in skewed
TCRBV gene families within PBMCs (CD4+ and CD8+
T cells) from subjects with active TB or LTBI were analysed
using the Kruskal-Wallis H test or nonparametric Mann–
Whitney U test. Differences in the data between two
TCRBV families were examined using a χ2-test or Student’s
t-test, with p < 0.05 considered statistically significant.
Results
Skewed TCRBV families within PBMCs, CD4+ and CD8+
populations
It is well known that the profile of TCRBV gene families in
PBMCs from healthy donors often shows a multipeak-
shaped pattern (Gaussian distribution) [14]. Moreover, no
significant differences between vaccinated and unvaccin-
ated subjects in both adult groups with active TB and
LTBI were reported. In this study, the skewed TCRBV
families were compared within the PBMCs, CD4+ and
CD8+ T cell subsets isolated from subjects with active TB
or LTBI. Of the three cell populations evaluated, the
TCRBV families in the CD4+ T cell subset contained a
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greater number of skewed clonally expanded TCRBV fam-
ilies. Moreover, the average number of skewed (oligoclonal
and monoclonal) TCRBV families in the CD4+ T cell
population was higher than that in the PBMCs and the
CD8+ T cell subset (p < 0.05, 0.01), and there was no sig-
nificant difference between the latter two cell populations
(Table 2).
In addition, there were fewer subjects with a normal
TCRBV pattern in the CD4+ T cell population compared
with the two other cell populations, and four TCRBV
gene families (BV12, BV13.1, BV13.2, and BV24) were
more prevalent than other TCRBV members in the three
cell populations derived from subjects with active TB or
LTBI (Table 2).
Skewed TCRBV profiles within CD4+ and CD8+
populations
A greater number of skewed TCRBV families was
expressed in the CD8+ T cell population from patients
with active TB than from those with LTBI (p < 0.05), and
Table 2 The frequencies of skewed TCRBV in CD4+, CD8+ T cells and PBMCs of the subjects with active TB or LTBIa
TCRBV families CD4+ T cells CD8+ T cells Total PBMCs
Incidence (%)b Incidence (%)b Incidence (%)b
1 8 5 7
2 9 8 7
3 14 (35.0) 8 11 (28.2)
4 7 5 7
5.1 15 (37.5) 9 12 (30.8)
5.2 7 9 8
6 8 5 6
7 7 6 4
8 10 (25.0) 7 6
9 7 5 3
10 7 6 8
11 8 3 7
12 24 (60.0) 16 (41.0) 21 (53.8)
13.1 16 (40.0) 12 (30.8) 12 (30.8)
13.2 15 (37.5) 13 (33.3) 15 (38.5)
14 11 (27.5) 8 8
15 9 5 7
16 7 5 2
17 6 6 5
18 10 (25.0) 9 8
19 7 7 5
20 14 (35.0) 8 11 (28.2)
21 7 5 6
22 7 6 5
23 10 (25.0) 7 8
24 16 (40.0) 10 (25.6) 12 (30.8)
Total no. of skewed BV (average ratio for a case) 266 (6.65) c 193 (4.95) c, d 211 (5.41) c, d
No. of subjects examined with normal pattern (ratio, %) 2 (4.76) e 3 (7.14) e 3 (7.14)e
No. of subjects examined 42 42 42
aThe number of TCRBV gene families showing skewed-clone expansion (oligoclonal or monoclonal) is summarized in subjects with active TB or LTBI.
bThe number of samples showing a skewed-clone expansion in total detected samples (percentages of each TCRBV skewed-clone expansion). Sample with normal
GMSP (no skewed-clone expansion pattern in any TCRBV families in a subject) are excluded in the percentage calculation, and the greater than or equal 25%
percentages are shown only.
cThe average expansion rate of TCRBV gene families was higher in CD4+ T cell subset than in other two cell populations (P < 0.01, 0.05 by χ2 test).
dThere was no significant difference between the two groups (P > 0.05 by χ2 test). Sample with normal GMSP (no biased-clone expansion pattern) are excluded in
the average ratio calculation.
eThe incidence of the normal GMSP was significantly lower in CD4+ T cells than in other two cell populations (P < 0.01 by χ2 test).
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there was no significant difference in skewed TCRBV
families in the CD4+ T cell population between subjects
with active TB or those with LTBI (p > 0.05) (Table 3).
To further distinguish the skewed expansion features of
the TCRBV family in active TB and LTBI subjects, the
profile of oligoclonal and monoclonal expansion of
TCRBV families from CD4+ and CD8+ T cells was
analysed. We found that there was a higher number of
monoclonal expansion TCRBV patterns in the CD4+
fraction compared with the CD8+ fraction in active TB
patients (Figure 1). Regarding LTBI subjects, there was
also a higher number of oligoclonal TCRBV patterns in
the CD4+ T cell subset (Figure 2).
Relative frequency of each TCRBV family in PBMCs
The relative percentage (%) of a TCRBV family deter-
mined the relative frequency in PBMCs derived from
active TB and LTBI subjects. We observed that the
frequency of most TCRBV families was not significantly
different between the two groups. Furthermore, we
found that the frequency of TCRBV families (BV7) in
the LTBI group was lower than that in the active TB
group (p < 0.01). However, the former group had three
TCRBV families (BV5.1/BV14/BV20) with higher expres-
sion than that of the latter group (p < 0.01) (Figure 3).
TCRBV CDR3 motifs in PBMCs, CD4+ and CD8+
populations
When the profile of a TCRBV gene family expressed a
monopeak-shaped pattern, the TCRBV family was
cloned, sequenced and translated to the corresponding
amino acid sequence. Representative amino acid se-
quences of TCRBV CDR3 in PBMCs, CD4+ and CD8+ T
cell populations from active TB and LTBI subjects are
shown in Tables 4 and 5, respectively.
Of the three cell populations from active TB and LTBI
subjects, four TCRBV gene families (BV12, BV13.1,
BV13.2, and BV24) were more prevalent than others.
The amino acid sequence of some mono-clone expan-
sion BV24 CDR3s were expressed as “SDRVSPL” with
BJ1.6 or “QDRAKQ” with BJ2.1, and BV12 CDR3 were
found expressed as “KQGDSYEQ” with BJ2.7 in active
TB patients. Additionally, there were no identical amino
acid sequences found in TCRBV13.1 and BV13.2 gene
families in PBMCs, CD4+ and CD8+ T cell populations
from active TB or LTBI subjects.
In addition, TCRBV5.1 and BV20, which were mainly
derived from PBMCs or CD4+ T cell subsets in active TB
and LTBI subjects, were predominant among all TCRBV
families. Furthermore, the majority of CDR3 amino acid
sequences of TCRBV5.1 and BV20 were expressed as
“LDYSGNTI” with BJ1.3 and “TGTGHSPL” with BJ1.6,
respectively. Similarly, the TCRBV3 family, with the ma-
jority found in PBMCs or CD4+ T cell subsets, was more
Table 3 Average ratio of skewed TCRBV gene families in











Total no. of skewed TCRBV 143 117 123 76
Total no. of subjects detected 22 22 20 20
No. of subjects examined with
normal pattern
1 1 1 2
Average ratio of skewed TCRBV (no.









aThe rate of skewed TCRBV family was not significantly different between the
two groups (P > 0.05 by χ2 test).
bThe rate of skewed TCRBV family was higher in active TB group than that in
LTBI group (P < 0.05 by χ2 test).
Figure 1 Comparing the number of skewed TCRBV family
between CD4+ and CD8+ T cell subsets in active TB patients.
Values are means ± STD. **P <0.01. CD4+ cell, purified CD4+ T
lymphocytes; CD8+ cell, purified CD8+ T lymphocytes.
Figure 2 Comparing the number of skewed TCRBV family
between CD4+ and CD8+ T cell subsets in LTBI individuals.
Values are means ± STD. **P <0.01. CD4+ cell, purified CD4+ T
lymphocytes; CD8+ cell, purified CD8+ T lymphocytes.
Yang et al. BMC Infectious Diseases 2013, 13:423 Page 5 of 10
http://www.biomedcentral.com/1471-2334/13/423
prevalent than other TCRBV families, but there were no
identical amino acid sequences found in this family.
However, among all the skewed TCRBV14 families in
PBMCs, CD4+ and CD8+ T cell populations from active
TB patients, there were no mono-clone TCRBV gene
families detected. Similarly, there were no mono-clone
TCRBV gene families detected among skewed TCRBV23
in LTBI subjects.
Discussion
Tuberculosis (TB), a major cause of global mortality, has
become increasingly prevalent and deadly due to the
emergence of extensive drug resistant strains of MTB
and the HIV/AIDS pandemic [20]. It has been reported
that CD4+ T cell-mediated immunity plays a critical role
in controlling chronic bacterial and viral infections
[10,21-24]. In the present study, we showed that the use
Figure 3 Relative frequency of each TCRBV family in active TB or LTBI subjects. TCRBV family in PBMCs derived from active TB patients or
LTBI individuals were shown as open bars or filled bars respectively. Data are presented as % expression of each TCRBV family relative to the total
expression of all 24 TCRBV genes (1 ~ 24). The data represent the means and standard deviation. **P <0.01.
Table 4 Representative amino acid sequences of monoclonal TCRBV families within PBMCs and CD4+, CD8+ T cell
populations of active TB patientsa
Patientsb Vbeta CDR3 BJ Ratioc
J1 (CD4+) BV24 AAMYLCATS SDRVSPL HFGNGTRLTVTED 1.6 21/25
J16 (CD4+) BV24 AAMYLCATS QDRAKQ YFGPGTRLLVLED 2.1 20/23
J5 BV23 SALYFCASS NTGTSDGY TFGSGTRLTVVED 1.2 21/25
J2 (CD4+) BV23 SALYFCASS NTGTSDGY TFGSGTRLTVVED 1.2 20/23
J2 BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 25/26
J5 BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 23/26
J5 (CD4+) BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 21/26
J15 BV13.2 TSVYFCASS YGPSTGEL FFGEGSRLTVVED 2.2 20/23
J11 (CD8+) BV13.2 TSVYFCASS YSTDEQ YFGPGTRLTVTED 2.7 18/26
J22 BV13.1 TSVYFCASS YWGSDTQ YFGPGTRLTVLED 2.3 17/25
J13 BV12 TSVYFCAIR KQGDSYEQ YFGPGTRLTVTED 2.7 14/22
J17 (CD8+) BV12 TSVYFCAIR KQGDSYEQ YFGPGTRLTVTED 2.7 18/24
J20 (CD4+) BV12 TSVYFCAIR KQGDSYEQ YFGPGTRLTVTED 2.7 17/22
J5 BV5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 20/26
J1 (CD4+) BV5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 21/25
J3 (CD8+) BV5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 19/21
J10 BV3 SMYLCASS LGARLSNQPQ HFGDGTRLSILED 1.5 16/21
J4 (CD8+) BV3 SSNFCSTT LIGRAGATRA YFGPGTRLTVTED 2.7 20/25
aWhen the GMSP profile of a TCRBV family displayed a single peak, the corresponding PCR products re-amplified, and the CDR3 were sequenced after cloning.
bThe T cell subsets (CD4+ or CD8+) for analysis are indicated in brackets.
cThe amino acid sequences of the max rate of TCRBV families are shown.
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of our gene melting spectral pattern (GMSP) assay to
study TCRBV gene families in PBMCs, CD4+ and CD8+
T cell subsets from subjects with active TB or LTBI was
helpful in the differential diagnosis and treatment of
active TB or LTBI. However, this will need to be further
confirmed in a larger cohort.
T cells are a core component of adoptive immunity.
They are divided mainly into two subsets, CD4+ and CD8+
T cells, and there are characteristic TCR molecular chains
expressed on their respective cell membranes [25,26]. In
the peripheral blood of healthy donors, the TCR in more
than 95% of T cells is composed of alpha and beta chain
heterodimers. Each T cell clone expresses a unique TCR
that recognizes antigen-derived peptides bound to the
major histocompatibility complex (MHC). The TCR has
three complementary determining regions (CDR1, CDR2
and CDR3). CDR3 is the key determinant of T cell antigen
specificity and mediates T cell diversity [27,28].
Analysis of the TCRBV repertoire has been widely
used to characterize alterations in T cell repertoires in
the peripheral blood of subjects infected with bacteria or
viruses [29,30]. For instance, Wang et al. reported that a
highly diverse TCR repertoire may be an important
benchmark and target in the success of immune treat
human CMV infection [31]. Vigano et al. described that
the increased TCR renewal may provide the mechanistic
basis for the generation of high-avidity HIV-specific
CD8 T cells [32]. That the initial antiviral response in
humans is maintained for many years in latent virus
infected individuals was reported by Klarenbeek et al.
[33]. In addition, Naumov et al. examined the TCR rep-
ertoire of CD8 T cells reactive against the influenza A
viral epitope M1 (58–66) [34]. These studies were carried
out usually using the high throughput sequencing (HTS),
flow cytometry or molecular cloning techniques. In a pre-
vious study, we developed a GMSP assay to determine the
clonal expansion status of TCRBV genes in PBMCs, and
found that TCRBV11 may be associated with HBV replica-
tion in patients with chronic hepatitis B [15,35]. In the
present study, the GMSP assay was used to determine the
molecular property of skewed TCRBV gene families in
PBMCs and CD4+ and CD8+ T cell subsets from active TB
and LTBI subjects.
We directly analysed the degree of clonally expanded
skewed TCRBV families in PBMCs, CD4+ and CD8+ T cell
subpopulations from subjects with active TB or LTBI. We
found that the average number of skewed TCRBV families
for the three cell populations was 5.41, 6.65 and 4.95, re-
spectively. Also, the average number of skewed TCRBV
genes in the CD4+ T cell subset was significantly higher
than that in the other two cell populations. This indicates
that more CD4+ T cells contribute to the immune re-
sponse in active TB or LTBI subjects than the other two
cell populations. In addition, analysis of the TCR variable
Table 5 Representative amino acid sequences of monoclonal TCRBV families within PBMCs and CD4+, CD8+ T cell
populations of LTBI subjectsa
Subjectsb Vbeta CDR3 BJ Ratioc
J24 (CD4+) BV24 AAMYLCATS SDRVSPL HFGNGTRLTVTED 1.6 22/25
J23 BV20 SGFYLCAWS VQVGWGETQ YFGPGTRLLVLED 2.5 12/21
J24 (CD4+) BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 21/25
J28 (CD8+) BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 20/24
J38 BV20 SGFYLCAWS TGTGHSPL HFGNGTRLTVTED 1.6 22/25
J32 (CD4+) BV14 SLYFCASS PGTTQETQ YFGSGTRLLVLED 2.5 18/23
J25 BV14 SLYFCASS PGTTQETQ YFGPGTRLTVLED 2.5 15/23
J28 (CD8+) BV14 SLYFCASS RHTGGTEA FFGQGTRLTVVED 1.1 19/30
J29 BV13.2 TSVYFCASS YDENEQ FFGPGTRLTVLED 2.1 16/22
J31 (CD4+) BV13.2 TSVYFCASK TKPVGEQ FFGPGTRLTVLED 2.1 15/23
J42 BV13.1 TSVYFCASS YSAGGPNEQ FFGPGTRLTVLED 2.1 18/25
J34 (CD4+) BV12 TSVYFCAIR KQGDSYEQ YFGPGTRLTVTED 2.7 17/23
J35 BV12 TSVYFCASR VRLITNYGY TFGSGTRLTVVED 1.2 24/24
J39 (CD4+) BV12 TSVYFCATA GGAPGQPQ HFGDGTRLSILED 1.5 16/24
J23 BJ5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 22/27
J25 (CD8+) BJ5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 22/27
J30 BJ5.1 SALYLCASS LDYSGNTI YFGEGSWLTVVED 1.3 22/25
J24 BV3 SMYLCASG PNYYEQ YFGPGTRLTVTED 2.7 23/25
aWhen the GMSP profile of a TCRBV family displayed a single peak, the corresponding PCR products re-amplified, and the CDR3 were sequenced after cloning.
bThe T cell subsets (CD4+ or CD8+) for analysis are indicated in brackets.
cThe amino acid sequences of the max rate of TCRBV families are shown.
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gene repertoire in blood or tissues may provide important
information about the immune response against patho-
gens or immunopathological mechanisms [30,36]. More-
over, it has been reported that multispecific CD4+ T cells
correlate with the control of MTB infections [9,12,37].
This suggests that the prevalent CD4+ T cells may be asso-
ciated with the kind of CD4+ T cells controlling MTB in
active TB or LTBI subjects, although, this will need to be
determined in more cases.
In addition, we found that in patients with active TB, a
higher number of monoclonal expansions were detected
in CD4+ T cells compared with the CD8+ T cell subset.
In LTBI subjects, the higher number of oligoclonal
expansions was found in the CD4+ T subset too. This
further suggests that CD4+ T cells may be associated
with the host immune response to MTB infection and
the different clinical manifestations between active TB
and LTBI [38,39].
The T-SPOT.TB assay has been used to diagnose sub-
jects with active TB or LTBI with high specificity and sen-
sitivity. However, the assay does not permit distinction of
active TB from LTBI [7,40], which has been tried by many
researchers. Sester, et al. attempted to distinguish active
TB from non-active states by the analysis of antigen-
specific CD4+ T-cell cytokine profiles in peripheral blood
[41], and Nemeth, et al. also want to discriminate between
active TB and other diseases using cytokine profile [42].
Delogu, et al. reported that the T cell response to a recom-
binant and methylated heparin-binding haemagglutinin
(HBHA) of MTB produced in M. smegmatis was useful in
discriminating between active and non-active TB disease
[43]. In this study, we found that the monoclonal expan-
sion of TCRBV23 was only detected in the peripheral
blood of patients with active TB, and TCRBV14 was only
detected in LTBI, which may help distinguish patients with
active TB from those with LTBI, although further studies
are needed, with a larger sample size to improve accuracy
of the method. In addition, between active TB and LTBI,
the average number of skewed TCRBV in the CD4+ T cell
subset did not differ significantly, but in the CD8+ T cell
subset, there was a statistically significant difference.
Recent studies have reported on the development of
TCR gene-modified T cells that allow the rapid gener-
ation of large numbers of cells with antigen-specificity
and functional avidity, with the potential for clinical
application [44-48]. The results of Luo showed that
M. tuberculosis 38-kDa antigen-specific HLA class I and
class II-restricted TCR genes can be successfully cloned
and transduced into primary CD4+ and CD8+ T cells
which result in T cells with stronger anti-MTB activity
[49]. Thus, characterization of the MTB-specific T cells,
especially their TCR gene usage [50], is essential for elu-
cidation of the pathogenesis of active TB or LTBI and
for the development of individualized treatment.
In the present study, we found that the skewed popula-
tions expressing the TCRBV12/BV13.1/BV13.2 or BV24
molecule were most prevalent compared with cell popula-
tions expressing other TCRBV gene families, regardless of
the CDR3 in PBMCs, CD4+ or CD8+ subsets from active
TB patients or LTBI individuals. Additionally, the fre-
quency of three TCRBV families (BV5.1/BV14/BV20) in
T cell populations in the LTBI group was higher than that
in the active TB group. It was reported that the repertoire
of TCRBV families present in patients with active TB
might be considered defective in controlling the pathogen,
since these patients are not able to control their infection.
Whereas those patients with LTBI have a TCRBV reper-
toire that shows differences in public or private TCR fam-
ilies, rendering them capable of controlling the growth of
the pathogen [11,51]. This indicates that high frequency
TCRBV families (BV5.1/BV14/BV20) may be associated
with immune control of the growth of MTB in LTBI
subjects.
We further analysed CDR3 amino acid sequences in
the monoclonal expansion TCRBV gene families, and
found that there were no identical sequences of CDR3
among the four TCRBV gene families, which indicates
that different T cell clones are involved in the immune
response to MTB. The reasons for this may include the
following: (1) there are different HLA phenotypes among
different MTB subjects, which lead to different epitopes in
MTB-specific immune T-cells, resulting in the prolifera-
tion of corresponding T cell clones; (2) there are various
and scattered antigenic epitopes in MTB that are related
to their pathogenicity and immunity; (3) the different se-
quences of CDR3 with similar spatial structure are likely
to recognize the same epitope. However, we found that
two CDR3 amino acid sequences had a relatively con-
served motif (BV5.1, “LDYSGNTI”; BV20, “TGTGHSPL”)
in PBMCs and CD4+ T cell populations from subjects with
MTB infection, although, at present, it is not clear if or
how the emergence of the relatively conserved TCRBV
gene families influence the course of active or latent MTB
infection and their prognoses.
Conclusions
In the present study, we showed that the role of T cells
in the immune pathogenesis of active TB or LTBI was
complex and multi-specific. Analysis of TCRBV expres-
sion in CD4+ T cells was more useful in assessing the
status and specificity of circulating T cells in subjects
with active TB or in those with LTBI. The expression of
TCRBV14, BV23 and the sequencing of CDR3 amino
acid motifs of TCRBV5.1, BV20 could help in the differ-
ential diagnosis and treatment of active TB or LTBI,
although, this should be confirmed in more cases, and
with non-TB being excluded from LTBI subjects [11].
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